The Correlate of Risk Targeted Intervention Study

Key facts

Sponsor

University of Cape Town

Principal Investigator

Mark Hatherill, MD, FCP (SA)

South African Tuberculosis Vaccine Initiative

Intervention

Isoniazid(drug)

Enrollment

2927 target

Eligibility

18-60 years · All sexes

Timeline

2016 – 2019

Study locations (5)

• Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa
• Aurum Institute, Klerksdorp, North West, South Africa
• Aurum Institute, Rustenburg, North West, South Africa
• Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa
• South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa

Collaborators

South African Tuberculosis Vaccine Initiative · Aurum Institute · Centre for the AIDS Programme of Research in South Africa · University of Stellenbosch · London School of Hygiene and Tropical Medicine · Fred Hutchinson Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07484490
  Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis
  Riphah International University
• RECRUITINGPHASE3NCT07209761
  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
  Otsuka Pharmaceutical Development & Commercialization, Inc.
• RECRUITINGPHASE2NCT07170800
  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
  WestVac Biopharma Co., Ltd.
• RECRUITINGPHASE2NCT06192160
  Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT06748937
  A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
  TASK Applied Science
• ACTIVE NOT RECRUITINGNANCT07186478
  I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
  Hasanuddin University
• ACTIVE NOT RECRUITINGPHASE3NCT06649721
  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
  Huashan Hospital
• RECRUITINGPHASE4NCT06476210
  The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
  Beijing Chest Hospital

See all trials for Primary pulmonary tuberculosis →